. 0107536001133 Ref. MD 126/2017 September 25, 2017 Re: Clarification on the operating performance of the Company and its subsidiaries for the nine-month period (3rd quarter) of 2016 (amendment) Attn: President The
46 (82) 883 n/a n/a 219 859 292% Net profit (loss) after NCI (40) (54) 654 n/a n/a 170 572 236% Performance without non-operating items 1 EBITDA 337 152 148 (3%) (56%) 797 753 (6%) 4Q17 % QoQ % YoY
revenue from money market product increased from foreign exchange transaction. Moreover, other operating expenses increased Baht 1,976 million or 2.98 percent over-year, due mainly to marketing expenses. 1
Microsoft Word - 044 ผลการดำเนินงานต่างเกิน 20% Q1-60 _ENG_ 260560_final - Translation - PorBor. 044/2017 May 26, 2017 Subject: Clarification of operating results different from the same period last
ที่ - Translation - PorBor.061/2017 August 15, 2017 Subject: Clarification of operating results different from the same period last year more than 20% To: President The Stock Exchange of Thailand
/2561 June 19, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q1/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited
/2561 August 7, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q2/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited
สารสนเทศรายการได้มาซึง่สินทรัพย์ บริษัท บางกอก เดค-คอน จ ากดั (มหาชน) (BKD) บริษัท แอสเซท โปร แมเนจเม้นท์ จ ากดั (APM) - หน้า 1 - Information Memorandum on Acquisition of Assets Reference is made to
” submitted to the SET on 6 th October 2017. 2. In July 2017, the government has announced a continuation of tax incentive program (Royal Decree 642) similar to last year. The investment in assets during the
Thailand Reference Letter: The Letter of the Company dated 10 April 2018 re: Acquisition and Disposition of Assets Pace Development Corporation Public Company Limited (the “Company”) would like to inform the